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Abstract | Antibacterial resistance is a great concern and requires global action. A critical
question is whether enough new antibacterial drugs are being discovered and developed.
A review of the clinical antibacterial drug pipeline was recently published, but comprehensive
information about the global preclinical pipeline is unavailable. This Review focuses on discovery
and preclinical development projects and has found, as of 1 May 2019, 407 antibacterial projects
from 314 institutions. The focus is on Gram-negative pathogens, particularly bacteria on the
WHO priority bacteria list. The preclinical pipeline is characterized by high levels of diversity and
interesting scientific concepts, with 135 projects on direct-acting small molecules that represent
new classes, new targets or new mechanisms of action. There is also a strong trend towards
non-traditional approaches, including diverse antivirulence approaches, microbiome-modifying
strategies, and engineered phages and probiotics. The high number of pathogen-specific and
adjunctive approaches is unprecedented in antibiotic history. Translational hurdles are not
adequately addressed yet, especially development pathways to show clinical impact of non-
traditional approaches. The innovative potential of the preclinical pipeline compared with the
clinical pipeline is encouraging but fragile. Much more work, focus and funding are needed
for the novel approaches to result in effective antibacterial therapies to sustainably combat
antibacterial resistance.
Lead generation phase
(hit-to-lead phase)
Drug discovery phase where
promising molecules (hits) are
evaluated and undergo limited
optimization to identify
suitable lead compounds.
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Resistance to antibiotics is a natural phenomenon that
has been noted since the introduction of penicillin in
the 1940s1. Whenever clinically relevant resistance has
emerged, the problem has been tackled with modification of existing antibiotic classes with limited cross-
resistance to existing drugs or introduction of new
classes2. The relative ease of the early antibiotic discovery
programmes and the financial rewards that followed created a wasteful and uncritical use of antibiotics without
adequate consideration of the societal consequences3.
After this ‘golden antibiotic era’, large pharmaceutical
companies faced major scientific challenges searching
for new antibiotics, especially with regard to penetration barriers and efflux mechanisms in Gram-negative
bacteria requiring high antibiotic doses with potential
associated toxicity issues4. These companies finally abandoned antibacterial drug discovery activities beginning
in the 1980s. Furthermore, they lost interest in a field
that did not promise ever-increasing market growth
and profits. Exits by large pharmaceutical companies
have caused concern among scientists, the health-care
community, civil society advocates and policymakers5,6.
Because of the long timelines for research and development, urgently needed responses and action can be calibrated only by knowing the global activities (and lack of
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activities) in antibacterial drug development. This mapping activity was initiated by the WHO with a recently
published global clinical antibacterial pipeline report7.
In contrast to the clinical pipeline, less is known about
the preclinical antibacterial pipeline. In this Review, we
analyse the preclinical antibacterial pipeline and provide
a current snapshot and decision support for all actors in
this field and some information on the broader context.
To assess the global preclinical bacterial pipeline,
we considered all projects from several databases and
research and development programmes (Box 1)
and included all antibacterial projects that were at least
in the lead generation phase (hit-to-lead phase) but had
not yet reached first-in-human studies. We grouped
all preclinical projects that met these criteria into the
following categories: direct-acting traditional agents
(traditional antibiotics that directly inhibit growth or
kill the bacteria); antibacterial vaccines, antibodies and
antibody–drug conjugates; phages or phage-derived
proteins and microbiota-modulating therapies; antivirulence agents that augment other agents; potentiators
that enhance and augment or transform other agents;
repurposed approved drugs; and immunomodulators
that are developed for a bacterial disease8–15. We also
looked at the type and location of institutions carrying
volume 18 | May 2020 | 275
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Box 1 | Assessment criteria of the global preclinical antibacterial pipeline
The basis of this Review was five databases or programmes with information about
antibacterial preclinical research and development projects: the Center for Anti-
Infective Agents (CEFAIA; 1235 data), CARB-X funding proposals (804), REPAIR Impact
Fund funding proposals (80), ENABLE (10 projects with data provided by project owners)
and the Joint Programming Initiative on Antimicrobial Resistance (JPIAMR; 20 projects).
No projects from JPIAMR could be included because they did not meet the inclusion
criteria. The data span from September 2016 to February 2019 and all data were
updated if possible, with a cut-off date of 1 May 2019. In the case of overlapping data,
the most recent update was used. The sources for updates were confidential personal
communication, scientific abstracts, company websites, press releases and scientific and
commercial publications. Whereas the JPIAMR, ENABLE and REPAIR Impact Fund data
were restricted geographically, the data from CEFAIA and CARB-X were global in scope.
Institutions were categorized as small and medium-sized enterprises (fewer than 1,000
employees), large companies (more than 1,000 employees), academic and other publicly
funded institutes, supported by philanthropic organizations or non-profit institutions,
and public–private partnerships. Companies and universities were counted as a single
institution even if they have subsidiaries in different countries or different departments
within a university. Israel was included in Europe for categorization purposes owing to
the strong research ties. The inclusion criteria require the project to target bacterial
infections and to be in the discovery (hit-to-lead and lead optimization phases ending
with declaring a preclinical candidate) and preclinical development phases for
submission of an application for clinical trial authorization (CTA) or an investigational
new drug application (IND), often called ‘CTA/IND-enabling studies’. Duplicates of
programmes due to collaborations, acquisitions or licensing were eliminated. Projects
were included only if the product had not had a first dose in humans before 1 May 2019
as evidenced by the aforementioned sources for updates and public clinical trial
registries. Also excluded were antibacterial products for non-human uses, diagnostics,
medical devices, conventional vaccines not focused on resistant pathogens
(such as vaccines against pneumococci, meningococci, Haemophilus influenzae),
new formulations and delivery methods of approved drugs (unless they allow new
antibacterial use that was not possible before), projects for label expansion of a product
already marketed or in clinical development, immunomodulators if not developed for a
specific bacterial disease, wound care products unless used as a first model to assess
the potential for other clinical indications, disinfectants and antibacterial ions. All data
on institutions and their programmes were anonymized and aggregated to prevent
tracking of data to specific companies or projects, as some companies request
confidentiality during preclinical stages.

Repurposed approved
drugs
Repurposing a drug is a
strategy for identifying new
uses for an approved drug that
are outside the scope of the
original indication.

Label expansion
Aims to achieve additional
regulatory approval for a new
indication beyond the original
use for which the drug was
approved.

Indications
A therapeutic indication refers
to the use of a drug for treating
a particular disease. The
indication can be approved
by regulatory agencies or
not approved.

Spectrum
Range of activity against
a group of bacteria.
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out the project. Finally, we further assessed the planned
indications, spectrum and formulations and the stage of the
project.
Overall, the current preclinical antibacterial pipeline
consists of 407 highly diverse projects from 314 institutions, most of which are small and medium-sized
enterprises (SMEs). Less than half of the projects involve
direct-acting small molecules and encouragingly 70% of
these aim at new targets (Fig. 1). In the following sections,
we discuss the characteristics of the institutions and then
go through the different project classes, highlighting
the risks and potential of the preclinical antibacterial
pipeline.

Institutions
Three hundred and fourteen research and development
institutions are working on at least one preclinical antibacterial programme that met our inclusion criteria
(Box 1; Fig. 2a). Most of these institutions are SMEs, comprising 255 companies (81% of all institutions), and most
of these SMEs are based in North America (United States
and Canada; 56%) and Europe (including Israel; 36%).
European SMEs were found most often in the United
Kingdom, followed by France, Switzerland, Denmark
and the Netherlands (Fig. 2b). Although we could not

verify the exact number of employees at SMEs in 5% of
cases, at least 60% of all included SMEs are very small
companies with fewer than ten employees. Ninety per
cent of the SMEs with a known number of employees
(n = 243) are small companies with fewer than 50 employees. Only 5% of the SMEs have more than 100 employees
but fewer than 500 employees. These numbers show that
the great majority of the world’s preclinical antibacterial
pipeline is in the hands of very small companies with very
limited financial (and workforce) resources.
Given the small size of most SMEs it is not surprising that they predominately focus on only antibacterial
research and development, mostly based on one specific
technology (Supplementary Fig. 1). A few have additional discovery projects in other anti-infective areas
(for example, antivirals). Some SMEs work in one or
more additional therapeutic areas, especially immuno-
oncology and/or inflammation. The distribution of these
three categories (only antibacterial therapy, only the
anti-infective field, or both antibacterial and other therapeutic areas) is similarly distributed among European
and North American SMEs.
Other types of institutions besides SMEs included 37
academic institutions, 10 large companies (more than
1,000 employees), 8 non-profit research institutions and
4 public–private partnerships (Fig. 2a). Most academic
institutions were excluded as their projects were not
advanced enough to meet the inclusion criteria. Very
few global pharmaceutical corporations have active clinical development programmes according to their published pipelines (for example, Pfizer, GlaxoSmithKline,
Medimmune/AstraZeneca, Genentech/Roche). Most of
these companies are not active in preclinical antibacterial research and development, although it is possible
that the companies are especially adept at keeping their
programmes confidential and did not apply for funding. The large pharmaceutical companies (more than
1,000 employees) included in this study and engaging
in preclinical antibacterial research and development are
mainly located in Asia and Europe and have a regional
focus. From our review of the data, these particular preclinical projects do not represent a renaissance in interest
by large companies in antibiotic resistance. Therefore,
SMEs carry out the great majority of the pipeline, with
few employees and dependence on one programme or
technology. This vulnerability is commonly characterized not only by a narrow set of expertise and dependence on the success of a single or a few similar prioritized
projects, but also by the need for continued flow of funding, mostly grants, as private funding is relatively modest
in preclinical antibacterial research and development.
This situation causes high volatility of the number of
SMEs and threatens the stability of the early pipeline.

Antibacterial preclinical programmes
Of the 407 preclinical projects that we identified, 81%
are in SMEs and 4% are in larger companies, and they
fall into seven broad categories (Fig. 3). One hundred and
eighty-seven projects (46%) involve agents that inhibit
or kill bacteria directly (‘traditional antibiotics’), 33 projects involve phages or phage-derived peptides that affect
bacteria directly, 33 projects involve agents that do not
www.nature.com/nrmicro
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407 preclinical antibiotic projects from
314 institutions (81% small and medium-sized enterprises)

++

46%

14%
8%

Direct-acting
small molecules
• ~70% new
and ~20% old
targets
• ~50% targeting
Gram-negative
bacteria

13%
8%

4%

Repurposed
Potentiators
• β-Lactamase or drugs
• FDA-approved
eﬄux pump
drugs
inhibitors
• Expanding
spectrum
• Enhancing or
restoring
activity
• Protectors

3%
Antibodies and
vaccines
• Against select
pathogens

• Scientiﬁcally interesting
• Research intensive
• Translational challenges
• Focused on resistance

Immunomodulators
• Support
pathogen
elimination

Antivirulence
approaches
• Adjunctive
• Targeting
diﬀerent
virulence
factors and
strategies
• Against select
pathogens

Phages and
microbiota
• Phages
against select
pathogens
• Endolysins
• Modulators of
microbiota
(mostly gut)

• Pathogen speciﬁc
• Adjunctive
• Long timelines
• Dependent on funding

Fig. 1 | Overview of the preclinical antibacterial pipeline. We identified 314 research and development institutions
and 407 preclinical projects. The projects were categorized according to their main effect on bacteria into the following
groups: direct-acting agents, antibodies and vaccines, phages and phage-related products, microbiota-modulating
therapies, antivirulence approaches, potentiators of direct-acting drugs, repurposed drugs, immunomodulators or others.
The high diversity of approaches provided is innovative but carries high translational risks.

Formulations
Pharmaceutical formulation is
the process in which the active
compound and additional
ingredients are combined to
produce a final medicinal
product.

Parenteral application
Route of administration other
than the gastrointestinal tract
to achieve systemic
distribution.

Intravesical application
Administration of a drug
directly into the bladder.

inhibit or kill bacteria directly but affect a broad range
of virulence factors, 29 projects involve antibodies and
antibody–drug conjugates, 27 projects involve antibacterial vaccines in preclinical development, 32 projects involve compounds that potentiate another drug,
usually an existing antibiotic, 21 projects are studying
microbiota-modulating approaches for different conditions, mostly focused on the gut microbiota, 15 projects
are ongoing for repurposed non-antibiotics or antibiotics
repurposed in combinations or developed for different
fields or applications, 12 projects are aiming to modulate the immune system to support the elimination of
pathogens and 18 projects are pursuing other strategies
(for example, nanoparticles). Almost 40% of the projects
are focused on pathogen-specific approaches, which is
unprecedented in antibiotic history.
The discovery phases (hit-to-lead and lead optimization
phases ending with declaration of a preclinical candidate)
and preclinical development phases (clinical trial authorization (CTA) or investigational new drug application
(IND), often called ‘CTA/IND-enabling studies’) are relatively evenly distributed and show a steady flow towards
first-in-human studies. The geographical distribution
across development phases is shown in Fig. 3b.
In the discovery phases, potential indications are
often not decided yet as they depend on the achieved
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spectrum of the compound. Therefore, we applied
general terms for indications (Fig. 3c), such as infections caused by Gram-negative bacteria, or infections
caused by Gram-positive bacteria, mostly skin and soft
tissue infections. Other indications include infections
caused by Neisseria gonorrhoeae, Helicobacter pylori and
Salmonella species.
Most new therapies will be formulated for
parenteral application (mostly intravenous) (Fig. 3d) .
Vaccines with intramuscular application are included in
this group. Agents with both intravenous and oral formulations were rare, and oral application was planned
in only 10% of projects. Formulations for local administration include oral non-absorbable compounds
and intravesical application. Inhalation is planned for
29 drugs (7%). Local administration may avoid pharmaco
kinetic and/or toxicological challenges of systemic drug
exposures.
Direct-acting agents. One hundred and eighty-seven
projects involve traditional antibacterial agents that
directly target bacteria by inhibiting or killing them without requiring any additional therapy. Characteristically,
these compounds are synthesized or natural chemicals of mostly small size and they follow a traditional,
well-known regulatory development pathway. These
volume 18 | May 2020 | 277
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a All institutions

Total 314 institutions

Small and medium-sized
enterprises (<1,000 employees)

81%
12%

Academic institutions
Large companies
(>1,000 employees)

3%

Non-profit institutions

3%

Public–private partnership 1%
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%

b Small and medium-sized enterprises
Netherlands: 5
USA: 136

Canada: 7

Denmark: 7
Switzerland: 10

UK: 27
France: 12

India: 8

Other countries: 43

Fig. 2 | Type and location of institutions that carry out preclinical antibacterial
development. a | The large majority of institutions involved in the preclinical discovery
and preclinical development of antibacterials are small and medium-sized enterprises
(255 of 314 institutions in total). Academic institutions, large companies, non-profit
institutions and public–private partnerships are comparatively under-represented.
b | More than half of the small and medium-sized enterprises are located in North
America, followed by Europe as the second most prominent continent. The European
countries with five or more companies are the United Kingdom, France, Switzerland,
Denmark and the Netherlands.

Non-fermenters
Heterogeneous group of
bacteria which cannot use
glucose and thus are unable
to generate energy through
fermentation of glucose.
Important genera of non-
fermenters include
Pseudomonas and
Acinetobacter.

Phase III trials
In clinical development,
phase III clinical trials are
randomized controlled
multicentre studies that assess
the effectiveness and safety of
a drug in comparison to
current standard-of-care
treatment.
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direct-acting drugs can be further classified into three
groups: improved derivatives of known antibiotic classes
(old targets), new chemical classes with new targets and
unknown or undefined agents with unclear targets
(Fig. 4a). The group of old targets (n = 35, 19%) includes
β-lactams and other inhibitors of penicillin-binding
proteins, fluoroquinolones and novel bacterial topo
isomerase inhibitors, aminoglycosides, polymyxins and
macrolides16. One hundred and thirty-five projects (72%)
are focused on new targets, including synthetic and natural antimicrobial peptides (AMPs), natural products and
LpxC inhibitors (as discussed below). Other new targets
include new binding sites in the bacterial ribosome, the
membrane, the cell wall, transcription and/or translation, gene interference and metabolism17–20. Some of
these targets and scaffolds were described a long time ago
but were not pursued to clinical development. Seventeen
projects involving direct-acting agents could not be
grouped due to insufficient information. Almost half
of the projects are focused broadly on Gram-negative
bacteria (enterobacteria and non-fermenters), and ~10%
are focused on Gram-positive bacteria (mostly staphylococci), which are not a critical priority according to

the WHO priority list21. The cell wall of Gram-negative
bacteria is an effective barrier to molecules that need to
penetrate the outer and inner membranes. Therefore, the
scientific challenges for targets residing in the cytoplasm
or inner membrane are greater than those for novel targets located in the periplasm or in the outer membrane.
Not surprisingly, there is a noticeable trend towards targets in the outer membrane in preclinical projects. As
mentioned before, in early drug discovery the spectrum
of activity cannot be defined exactly and may change
during the lead optimization phase. About 22% of the
projects involve pathogen-specific approaches (mostly
against Gram-negative bacteria) and thus face specific
challenges to recruit enough patients for phase III trials
compared with trials of drugs with a broader spectrum.
About 10% of the projects have a broad spectrum covering a broad range of both Gram-positive bacteria and
Gram-negative bacteria (Fig. 4b).
Within the group of direct-acting compounds, three
defined clusters are noticeable: synthetic or natural
AMPs, natural products and LpxC inhibitors. The naturally abundant and diverse AMPs are a well-known
group of antibacterials and are the basis for semisynthetic peptide molecules and peptidomimetics18,22–25.
Such renewed interest in this group may help to overcome some of the obstacles of AMPs such as high cost of
synthesis, short half-life in vivo due to their susceptibility to proteolytic degradation and issues with toxicity26.
Natural products are mainstays of our current antibiotic
arsenal, exemplified by the large group of β-lactam antibiotics, aminoglycosides, tetracyclines and macrolides.
Modern technologies such as genome mining contri
bute to the discovery of new scaffolds, and technical
innovations are revealing new chemistry and increased
yields, all of which contribute to the revival of natural
product programmes27–29. LpxC inhibitors, which target the first dedicated step in the synthesis of lipid A,
have been explored since the mid-1990s but no drug has
advanced yet beyond phase I clinical trials. Development
of ACHN-975 was discontinued after a phase I trial,
owing to local inflammation at the injection site and
some toxicity signals in the mouse model30–32. A trial
involving RC-01, another LpxC inhibitor, was recently
terminated for safety reasons33. Despite LpxC being a
good target, toxicity of the used chemical matter seems
to be a major challenge, but a growing body of knowledge and experience may help to overcome some of the
current hurdles, including recent donations facilitated by
CARB-X of toxicology data on the recently failed LpxC
inhibitor into the public domain (the Shared Platform
for Antibiotic Research and Knowledge (SPARK), Pew
Trusts). In general, novel targets or novel chemicals carry
the risk of unpredictable toxicity, because the translat
ability of safety signals from preclinical models to humans
is uncertain, as exemplified by the aforementioned
LpxC inhibitor RC-01 (ref.32). The recent termination
of the phase III clinical trial of the novel Pseudomonas
aeruginosa-specific LptD inhibitor murepavadin due
to higher than expected rates of acute kidney injury
demonstrates the challenges of unexpected toxicity
of a new chemical that was not predicted from earlier
preclinical studies or from studies in healthy individuals34.
www.nature.com/nrmicro
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Metallo-ß-lactamases
ß-Lactamases that require zinc
for activity and hydrolyse
penicillins, cephalosporins
and carbapenems.

a

Potentiators. Potentiators are drugs that have no or
insufficient antibacterial activity alone but transform,
restore or augment the activity of another antibiotic.
Well-known examples include β-lactamase inhibitors35,36;
of note, there are no approved inhibitors that include
metallo-ß-lactamases37. Twelve projects are focused on
inhibiting β-lactamases, including metallo-β-lactamases
(Supplementary Fig. 2). Some of the β-lactamase inhibitors are planned to be delivered orally. Although extensively researched, no inhibitor of various efflux pumps38
has been clinically developed so far39. Five efflux inhibitors targeting different efflux pumps are included in this
list of potentiators. Other approaches in the preclinical
b
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Repurposed drugs. We identified 15 projects involving
repurposed drugs. Repurposed drugs are drugs that are
approved for other disease areas or antibacterial drugs
that have not been tested or not used for a specific purpose before. They could be developed in combination,
as drug conjugates or in new formulations that allow

180

Potentiators

Vaccines

pipeline are potentiators that expand the spectrum (for
example, developing Gram-negative activity from anti-
Gram-positive drugs), enhance the activity substantially,
restore the activity against resistant bacteria or protect
against nephrotoxicity of nephrotoxic antibiotics, such
as colistin or aminoglycosides.

Hit to lead
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Infection with Gram-negative bacteria
Infection with Gram-positive bacteria
Cystic fibrosis

20%

Parenteral

Clostridioides difficile infection

Intravenous and oral

Urinary tract infection
Hospital-acquired/ventilatorassociated pneumonia
Tuberculosis

43%

5%

Oral
Local

7%

Inhalation
Topical skin

Implant-associated infection

12%

Respiratory tract infection

Undefined
10%

3%

Other
Undefined
0

20

40

60

80

100

120

Fig. 3 | Antibacterial approaches, development phase, indications and
routes of administration in the preclinical pipeline. a | Fewer than half
of the projects (187 , 46%) involve direct-acting antibiotics, 33 projects
involve phages or phage-derived peptides that affect bacteria directly ,
33 involve agents that target virulence factors, 29 involve antibodies and
antibody–drug conjugates, 27 involve antibacterial vaccines, 32 involve
potentiators of another antibiotic, 21 involve microbiota-modulating
therapies, 15 involve repurposed non-antibiotics or antibiotics that have
not been used in systemic bacterial infections of current interest before,
12 involve immunomodulators and 18 others could not be classified in
the above classes, such as nanoparticles to support the elimination of
pathogens. b | Most institutions that conduct preclinical antibacterial
research and development are based in Europe and North America.
Projects are relatively evenly distributed between the hit-to-lead, lead
optimization and preclinical development phases with clinical trial
NaTuRe RevIeWS | MicrObiOlOgy

authorization (CTA)- and investigational new drug application
(IND)-enabling studies with a trend towards relatively more projects in
the early phase in North America and more projects in the later phases
in Europe. c | Although the planned indications cannot be defined for all
preclinical projects, the ones that have a planned indication already
reflect the WHO priority list of pathogens for which new antibiotics
are needed, such as infections with no or few available treatment
options and that currently cause substantial morbidity and death,
and/or are difficult to treat. d | Most of the agents for which the route of
administration has already been defined will be applied parenterally
(mostly intravenously and in case of vaccines also intramuscularly). Fewer
projects will use oral administration (for systemic treatment, in a few
projects this is combined with intravenous treatment), inhalation, local
administration (mostly non-absorbable oral administration) and topical
formulation for the skin.
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Fig. 4 | Approaches and spectrum of preclinical direct-acting, small-molecule
antibacterials. a | Direct-acting small molecules in the preclinical antibiotic pipeline are
derivatives of ‘old chemical classes’. This group includes β-lactams and other penicillin-
binding protein (PBP) inhibitors, fluoroquinolones, novel bacterial topoisomerase
inhibitors (NBTIs), aminoglycosides, polymyxins and macrolides. Most direct-acting
antibacterials represent new chemical classes and/or have new targets. These small
molecules include large groups of synthetic and natural antimicrobial peptides, natural
products and inhibitors of LpxC, the first dedicated enzyme in lipid A synthesis. b | Most
direct-acting small molecules target Gram-negative bacteria (either with a broader
Gram-negative spectrum or pathogen specific). There are fewer molecules aimed at
Gram-positive bacteria or with a broad spectrum against both Gram-negative bacteria
and Gram-positive bacteria. The numbers for Neisseria gonorrhoeae, Clostridioides
difficile and Mycobacterium tuberculosis are shown separately.

different use12,40. The development process for repurposed drugs benefits from a large body of available
knowledge and reduces the time and cost of development12. The value of such an approach in the clinical
setting remains to be shown.

Endolysins
Enzymes that are produced by
bacteriophages and hydrolyse
the bacterial cell wall to escape
the cell at the end of the cycle.

Compassionate use
The use of unapproved drugs
outside clinical trials for
patients without options
of treatment with an
approved drug.
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Phage and phage-derived peptides. Twenty-seven institutions are working on the development of 33 phage or
phage-derived therapeutics. Phage therapies may contain natural phage cocktails (11 projects), engineered
phage cocktails (11 projects, some CRISPR enhanced)
and other highly diverse scientific approaches (Fig. 5a).
The most common phage-derived products are phage
endolysins against Staphylococcus aureus, with relatively
fewer projects on recombinant lysins against Gram-
negative bacteria. Phage therapies are species specific
and thus the most common targets of the programmes
were P. aeruginosa and S. aureus, but phage therapies

for Clostridioides difficile infection and infection with a
wide range of other pathogens are also in development
(Fig. 5b).
Phage therapies have garnered a lot of attention lately
due to the successful treatment of a small number of
individual patients with chronic conditions limited to a
small number of experimental treatment centres, often
in compassionate use programmes10,41,42. Compassionate
use of personalized phage preparations is limited to specific clinical circumstances and individual physicians
and researchers who have experience with phage therapy42. Patient-specific phage cocktails allow the use for
rare pathogens, whereas recombinant lysins may cover a
broader spectrum of Gram-negative bacteria. Although
phages have been used historically in topical formulations (mostly skin)43, phage preparations are being developed for intravenous, aerosol or diverse locally applied
formulations44. The immense size of phages compared
with small-molecule antibiotics poses pharmacokinetic
challenges, and important scientific questions remain
regarding availability at the site of infection and determining the best dosing regimen45. In general, natural
and engineered phage cocktails dominate our sample.
New genetic tools such as CRISPR–Cas systems are
used to genetically engineer phages that infect diverse
hosts46. Phages are also used as species-specific carriers for a variety of potential antibacterial payloads47 or
CRISPR–Cas-based RNA-guided nucleases targeted at
resistance or virulence determinants48,49. Considerable
progress has been made recently in tackling the great
challenges in the chemistry, manufacturing and control
of therapeutic phages, especially in production, stability,
purity and quality control. However, challenges remain,
such as unique phage biology and specificity, pharmacokinetics of large self-replicating agents, rapid resistance development and translation to a broader group
of patients beyond compassionate use8. Also, patient-
specific phage therapy requires a highly developed diagnostic infrastructure (with phage-specific rapid testing).
Phage therapies will likely be restricted to well-defined
situations in individual patients or as adjunctive therapy
with all the challenges related to clinical superiority trials
that compare a usually highly effective standard of care
and adjunctive therapy versus standard of care alone50,51.
Phage-derived proteins such as endolysins are gaining attention52,53. Endolysins are bacteriolytic on contact
and are highly specific for a bacterial species or genus.
Endolysins directed against S. aureus are in clinical
development8 and follow the traditional clinical development path. Extensive protein engineering efforts have
expanded options to target Gram-negative bacteria54.
However, such projects are still uncommon and may
require more basic research55.
Microbiota-modulating therapies. Twenty-one different microbiota-modulating approaches are included in
this Review (Fig. 5c). The most common strategy is engineered probiotics (also called ‘live biotherapeutic products’) with potentially enhanced functional properties.
Other projects are focused on natural strains derived
from a healthy microbiota for a variety of potential beneficial effects. AMPs expressed in phage-based carrier
www.nature.com/nrmicro
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Fig. 5 | Phages and phage-derived therapeutics, microbiota-modulating approaches and antivirulence approaches
in the preclinical pipeline. a | The most commonly pursued approaches for phage therapy are phage cocktails (either
natural phages or engineered phages), engineered phage endolysins and phages that are used as carriers for antibacterial
payloads. b | The phages and phage-derived proteins in preclinical development target a large variety of different
pathogens and are usually pathogen specific. c | Microbiota-modulating therapies are mainly engineered probiotics or
selected natural bacterial strains from a healthy microbiota. We have also included phages as a carrier of antibacterial
payloads that specifically manipulate the microbiota in this category. Other microbiota-modulating approaches include
use of antibacterial compounds against specific bacteria in the microbiota, antibiotic inactivators in the gut and absorbers
of bacterial toxins in the gut, and faecal microbiota transplants (FMT). d | The spectrum of antivirulence compounds is
diverse and focuses on Pseudomonas aeruginosa, Enterobacteriaceae spp., Staphylococcus aureus and Clostridioides
difficile or, less commonly, is broad.

systems are another approach to modulate the microbiota by targeting specific members of the microbiota.
Antibiotic inactivators and absorbers of bacterial toxins
in the gut are also being pursued in preclinical projects.
Most microbiota-modulating therapies in preclinical development target the gut microbiota, especially
C. difficile. The lung, sinus or skin microbiota is rarely a
target of such approaches.
Recent advances in metagenomic, computational
and synthetic biology tools have allowed and inspired
the revival of research into the human microbiota56.
Microbiota-modifying therapies have been explored and
tested in patients using the entire healthy microbiota to
correct major imbalances and reduce the recurrence of
C. difficile infection57. Such programmes have recently
faced a setback as one patient died because of faecal transplants that contained drug-resistant bacteria58 and led to
the halting of clinical trials by the FDA. It is not fully
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known yet how this incident will affect regulation by the
FDA and consequently the entire field of faecal transplants
or similar strategies. There is a trend towards reducing the
complexity of faecal transplants by controlling the transfer of bacterial strains or selecting natural strains derived
from a healthy microbiota59,60. New techniques based on
synthetic biology and systems biology allow the precise
genetic engineering of well-known probiotics61, which
may also express specific antibacterial substances62–64.
A long-known strategy to maintain a healthy microbiota is the use of antibiotic inactivators or absorbers of
bacterial toxins in the gut. Examples include enzymes
that inactivate residues of specific systemic antibiotics
in the gut to reduce disbalance of the microbiota caused
by antibiotic therapy or absorbers of bacterial toxins that
may cause disease, such as toxins produced by C. difficile
or other pathogens64,65. Both strategies still need to prove
their value in the clinical situation51.
volume 18 | May 2020 | 281
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The drastically reduced complexity of new therapies
based on genetic engineering technologies but incomplete knowledge of the microbiota may hamper the
translation to an effective modulation of an extremely
complex system. On the other hand, highly synthetic
strategies reduce or avoid the risk of transferring potentially unwanted bacteria or other components of the
microbiota66. The challenges of microbiota-modifying
therapies are even more obvious when targeting bacterial communities beyond the gut microbiota. Validated
animal models to predict clinical outcome are lacking.
The entire microbiota field has seen great attention in
terms of investment and company formation, with a
potentially overly optimistic promise to cure a wide variety of diseases and generate high profits. In the infectious
disease field, we see some spillover of this enthusiasm.
Antivirulence therapies. The 33 antivirulence projects that we identified are pursuing a wide range of
strategies, including inhibition of quorum sensing,
biofilm formation, adhesion, diverse regulators and
persisters67–71. Antivirulence drugs need to be combined with a direct-acting antibacterial therapeutic and
are designed as adjunctive therapies. Most programmes
are specifically targeted at P. aeruginosa, S. aureus and
C. difficile. Some approaches target several members of
the Enterobacteriaceae family or have an even broader
spectrum (Fig. 5d).
The discovery phase of antivirulence therapies is
characterized by the difficult choice of the most relevant preclinical assays to define success in the absence
of bacterial death8,72. As surrogate outcomes may have
little evidence of relevance for clinical outcome, the risk
of failure in clinical trials is high. Validated animal models that would predict clinical outcome are usually not
available.
Additionally, many antivirulence programmes73,
similarly to phage therapies, are pathogen-specific and
often patient-specific approaches. They would require
not only advanced health-care systems but also specific
diagnostic capabilities that are beyond the currently
available and implemented ones, and there are few or
no plans to ensure timely development and deployment
of diagnostic tools to guide the potential clinical use of
new antivirulence therapies.
Antibodies and antibody–drug conjugates. Twenty-nine
projects are focused on antibodies, including antibody–
drug conjugates. Most antibodies are developed as prevention or adjunctive therapy for S. aureus infections,
followed by C. difficile and P. aeruginosa infections, with
more than three programmes each. Less common are
antibodies against Acinetobacter species, Escherichia
coli and other bacteria. Eleven of these programmes are
already in late preclinical development.
Only three antibodies against bacterial infections
have been approved for clinical use so far8. They are
active against toxins of Clostridium botulinum, Bacillus
anthracis and C. difficile. All of these approved antibodies
neutralize toxins, the predominant or the only virulence
factor responsible for diseases caused by these pathogens. Antibodies against bacteria that have a multitude
282 | May 2020 | volume 18

of virulence determinants have yet to be successful. The
recent clinical failure of an antibody against several virulence factors of S. aureus74 exemplifies the challenges
of conducting superiority trials and showing efficacy
and clinical value of an adjunctive therapy. Similarly, it
is extremely difficult to show a meaningful clinical benefit when administering antibodies prophylactically. For
example, even in groups at high risk of postoperative
S. aureus infection, the number of infections is small,
and therefore large numbers of enrolled patients are
needed to make an overall effect visible in clinical trials.
Vaccines. Among the 27 vaccine projects, five target
S. aureus. Fewer than five projects are targeting P. aeruginosa, Acinetobacter species, Klebsiella pneumoniae,
N. gonorrhoeae and non-typhoidal Salmonella spp.
Several other projects are focused on single rare patho
gens. There are also multiantigen and/or multivalent
vaccines against groups of bacteria.
Some of the aforementioned challenges regarding
antibodies also apply to vaccines in development to prevent infections caused by multidrug-resistant pathogens.
Several bacterial vaccine trials have failed in late clinical
development owing to the lack of reliable preclinical
predictive models followed by insufficient clinical efficacy confounded by concurrent antibiotic treatment75,76.
Most targeted pathogens for current vaccine projects
have been classified as less well suited to vaccine development or as having unclear development feasibility by
a recent report that evaluated research and development
opportunities for vaccines9.
Other projects. This group of 18 projects includes nano
particles (nanobiotics) that have antibacterial capabili
ties. While nanoparticles and synthetic polymers are
well-known vectors to deliver drugs77,78, nanobiotics
are able to kill microorganisms directly through the
generation of reactive oxygen species, cell membrane
permeation, triggering DNA damage or interrupting
transmembrane electron transport79.

Conclusions
The preclinical antibacterial pipeline (Box 2) reveals innovative strategies when contrasted with the current global
antibacterial clinical pipeline, which mainly builds on
modification of known antibiotic classes. The preclinical
pipeline is characterized by a high level of diversity and
interesting scientific concepts compared with the clinical pipeline, although these projects may not necessarily
contribute to solving the problem of increasing resistance
to currently available antibiotics. The focus and goal of
most of the current projects acknowledge the need for
new therapies without cross-resistance to existing antibiotics. In sharp contrast to the clinical pipeline, more
than 70% of the direct-acting agents are new classes, have
new targets or have new mechanisms of action not used
so far in patients. Most of these ‘new’ approaches were
described decades ago but were not followed through to
clinical development.
The general goal and focus of preclinical development
programmes on Gram-negative pathogens correspond to
the need described in the WHO priority pathogen list21.
www.nature.com/nrmicro
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Box 2 | Main features of the preclinical antibacterial pipeline
• High level of diversity and interesting scientific approaches, much more so than the
clinical pipeline.
• Less than half of the projects involve direct-acting small molecules.
• More than half of the projects involve ‘non-traditional’, potentially adjunctive
therapies with an as yet unclear regulatory pathway to show a clinically relevant
benefit.
• Non-traditional approaches may not build on validated predictive preclinical models
and therefore have a higher risk of clinical failure.
• Focus on WHO critical priority pathogens (with the exception of antibodies, vaccines
and phages for Staphylococcus aureus).
• Strong trend towards pathogen-specific or patient-specific therapy requiring highly
developed health-care systems with advanced rapid diagnostic capabilities.
• Strong dependence on public and/or philanthropic funding.
• High volatility due to high-risk strategies and translational challenges pursued by
small companies.

A noticeable trend towards narrow-spectrum or even
pathogen-specific drugs points to the future need of a
highly developed diagnostic infrastructure that will be
able to provide meaningful and rapid diagnostic results
that impact the therapy decision. The challenges of
the clinical development and commercialization of a
narrow-spectrum or pathogen-specific drug are great
as recently exemplified by the new aminoglycoside plazomicin, which was tested in patients with infections
with carbapenem-resistant Enterobacteriaceae (mainly
K. pneumoniae)80. It was extremely difficult to enrol
patients with the specified resistant pathogens despite a
large number of patients being screened.
Although small molecules that inhibit or kill bacteria have been the mainstay of antibacterial therapy in
the past, ‘non-traditional’ approaches are increasingly
being revived and seen as alternatives to circumvent
the perceived scientific challenges of traditional anti
biotics against Gram-negative bacteria. Such approaches
are not new, and most preclinical programmes failed in
the past. The challenges of developing non-traditional
therapies have recently been reviewed8,51, highlighting
the fact that approaches used as adjunctive therapies
need to show their value in superiority clinical trials.
Most non-traditional approaches are currently planned
to be used as adjunctive therapies. As highly effective
standard-of-care antibiotics are available, an additional clinically relevant effect of the adjunctive therapy
(superiority) is extremely difficult to show. It is unclear
whether superiority compared with an active antibiotic
can be achieved in typical superiority design clinical
studies. Clinically meaningful additional end points
would need to be developed and validated. The required
availability of an active companion direct-acting antibacterial8,51,81 means that such adjunctive therapies are
not necessarily ‘alternatives’ and are not solving the
resistance problem directly, but promise specific effects
that have been shown in non-clinical studies but have
not yet been translated into relevant clinical effects8. In
most cases indirect-acting therapy concepts are based
on theoretical considerations, which are appealing and
well reasoned. However, predictive non-clinical models
that would guide the translational steps are not available.
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Innovative readouts or biomarkers have not been developed yet to measure the impact of these therapies. In
addition to the challenges mentioned, some approaches
require a delivery system to transport active agents to
the site of action, thus representing the challenge of two
new complex systems. Translating scientific results and
non-clinical studies into significant clinical benefits
will be the greatest challenge for most indirect-acting
non-traditional therapies.
Although this Review is the most complete analysis
and up-to-date description of the global antibacterial
preclinical research and development pipeline, some
limitations apply. Certain sectors, such as academic or
non-profit institutions, may be underrepresented in
the data, whereas other institutions may abandon their
discovery activities by closing the company or project
before any public disclosure. Some of our data sources
and programmes (REPAIR Impact Fund, ENABLE and
Joint Programming Initiative on Antimicrobial
Resistance) were limited to specific regions, mainly
North America and Europe. Although CARB-X accepts
applications from around the world, most of its applications are from North America and Europe, and some
institutions outside those regions may not have applied
for funding. Most of the data do not systematically
include tuberculosis, so those programmes are probably
underrepresented.
In conclusion, the preclinical development pipelines
are diverse and innovative compared with the clinical
pipeline, although this innovation does not necessarily
solve the most critical therapeutic problems and may
not translate to relevant clinical effects. The pipelines
are highly fragile in SMEs for many reasons. Major basic
scientific challenges such as penetration, efflux and the
associated risk of toxicity owing to required high doses
need an expanded concerted research agenda to advance
discovery efforts for traditional antibiotics. A large proportion of high-risk approaches have yet unknown ability to translate into clinical beneficial potential, which
may reduce future viable clinical pipelines. Basic scientific
and translational challenges cannot be solved by individual small companies and will require huge collabo
rative efforts of the entire drug discovery community.
Clear clinical development strategies may not exist for
some non-traditional approaches. Adjunctive therapies
require an active antibacterial drug and thus may not
solve the current resistance problem. A strong focus
on narrow-spectrum, pathogen-specific and patient-
specific therapies will require highly developed and well-
deployed diagnostics. These are not yet in view and may
be restricted to specific countries and environments,
primarily better-resourced environments. This Review
further reveals the overlap between the preclinical pipeline and the WHO priority pathogen list and the scope
of some funding calls that currently include specifically
high-risk approaches with unsolved translational challenges. A global public health perspective would improve
the potential medical value of future treatments. Many
antibacterial projects are scientifically exciting and innovative but as the translational challenges are extremely
great and most preclinical projects will fail to result in
approved and clinically relevant drugs, the preclinical
volume 18 | May 2020 | 283
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Push funding
Incentivizes discovery and
development activities before
achieving regulatory approval.

Pull incentives
Reward the successful
development and regulatory
approval of a new drug.
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pipeline is not adequately robust. Owing to numerous
discovery challenges, it is not surprising to find the
global antibacterial clinical pipeline populated with
modifications of existing classes of antibiotics that substantially de-risk programmes. Additionally, the dearth
of funding available for clinical development of antibacterial therapies contributes to barriers for progression of
preclinical projects to human trials after all the scientific
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